Welcome

to Oslo Medtech

Register here to subscribe to our newsletter!


 

First Name:
Last Name:
Email Address:
Subscribe
Unsubscribe

Oslo Medtech News

Generating innovation. For better living and health.

News Archive
Double victory for PCI Biotech

Adm. dir. i PCI Biotech, Per Walday (t.v.) mottar prisene av DnB NORs adm. dir. Rune Bjerke. (Foto: DnB NOR)PCI Biotech wins the Innovation Award of one million NOK. In addition, the company won the People's price of 100.000 NOK. The money will go to further research on the company's treatment for cancer. PCI Biotech is working intensely to deliver a new treatment against cancer. In cooperation with the Norwegian Radium Hospital has PCI Biotech developed and patented a photosensitive drug that allows the local treatment of cancer tumors. The cure may enhance the effects of chemotheraphy up to a hundred times.

Read more at InnoDesign

PCI Biotech Holding ASA
PCI Biotech is an oncology-focused company developing combination products for localised cancer treatment. The products are based on PCI Biotech’s patented drug delivery technology, photochemical internalization (PCI), which can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells. The lead product, PC-A11, combines the proprietary photosensitiser Amphinex® with the well established cytotoxic agent bleomycin.

Head and Neck Squamos Cell Carcinoma (HNSCC) is the primary target population for further development of PC-A11, and the company is also working to establish other cancer indications, as well as other drug combinations, where the PCI technology could potentially meet a need of improved local cancer control.
 
Utviklet av React Solutions og designet av Rim Ide & kommunikasjon